Thanks DD. No, I haven't yet bought any shares but I am still keeping an eye on Medivir and have them up near the top of my watchlist. I still think Medivir is the best play right now in the HCV space, given their position and valuation. I think the biggest risks to Medivir's valuation are the usual risks of a safety issue cropping up in Phase 3 trials, or in the combo trial with the VRUS nuke, or growing belief that the VRUS nukes alone will dominate future HCV treatment.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.